Nitroxoline Derivatives for Drug-Resistant Bacteria and Bladder Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The emergence of bacterial resistance to existing antibiotics and the need for new compounds with enhanced antitumor activity against multidrug-resistant bacteria and tumors, particularly bladder cancer, is a pressing challenge in clinical practice.
Innovation Solution
Development of nitroxoline derivatives with specific substituent groups (R1, R2, R3, R4, R5) that exhibit improved antitumor and antibacterial activity, synthesized through various reaction methods, including heating in solvents and demethylation reactions, to enhance their therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nitroxoline is used to treat bacterial infections, then antibacterial activity is achieved, but bacterial resistance develops over time
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of nitroxoline through substitution at different positions (R1-R5) with various functional groups. This structural parameter modification creates derivative compounds with altered biological properties that maintain antibacterial activity while overcoming resistance mechanisms developed against parent nitroxoline.
Solution Approach 2:
The invention creates composite chemical structures by combining the nitroxoline core scaffold with diverse substituent groups (halogens, alkyls, aryls, heterocyclyls, etc.). These composite molecular structures exhibit enhanced and diversified antibacterial activity against resistant strains, effectively treating infections that are resistant to conventional nitroxoline.
2Reliability
If nitroxoline is used for tumor treatment, then antitumor activity is achieved, but enhanced efficacy against multidrug-resistant tumors is needed
Solution Approach 1:
The patent employs parameter changes by modifying molecular structure parameters of nitroxoline to create derivatives with improved pharmacological properties. The systematic variation of substituents at R1-R5 positions alters the compound's interaction with tumor cells and resistance mechanisms, enhancing antitumor efficacy against multidrug-resistant cancer lines including bladder and prostate cancer.
Solution Approach 2:
The invention applies local quality by introducing specific functional groups at particular positions (R1-R5) of the nitroxoline molecule to target specific biological pathways in tumor cells. This localized structural modification optimizes the compound's ability to overcome multidrug resistance while maintaining selective antitumor activity.
3Reliability
If nitroxoline derivatives are synthesized with multiple substituent groups, then antitumor and antibacterial activity is improved, but synthesis complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the synthesis into modular stages: first establishing the nitroxoline core structure, then sequentially introducing substituent groups at R1-R5 positions through separate reaction steps. This segmented approach allows systematic optimization of each position independently while maintaining overall synthesis manageability and facilitating structure-activity relationship studies.
Data Source
AI summary
The present invention discloses a nitroxoline derivative, a preparation method therefor, and use thereof. Specifically, the present discloses a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing same, and use thereof in treating infectious diseases or cancers. The compound of the present invention has excellent anti-tumor activity and antibacterial activity, and can be developed into a drug for treating tumors and infectious diseases. The definition of each group in general formula (I) is the same as that in the description.